{"DataElement":{"publicId":"6581905","version":"1","preferredName":"Liver Cancer AJCC Edition 8 Pathologic Tumor T Category","preferredDefinition":"Extent of the primary hepatocellular carcinoma and fibrolamellar carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.","longName":"LIVR_AJC8_PTH_T_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3179611","version":"1","preferredName":"Liver Cancer Pathologic T Stage","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._Pathologic; caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"2834593v1.0:2207099v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2834593","version":"1","preferredName":"Hepatocellular Carcinoma","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","longName":"C3099","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62421A44-5466-782E-E040-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207099","version":"1","preferredName":"Pathologic T Stage","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C25610:C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1838-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98A7B501-CBC3-2349-E040-BB89AD430DBA","latestVersionIndicator":"Yes","beginDate":"2010-12-30","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-30","modifiedBy":"TAYLORT","dateModified":"2018-12-19","changeDescription":"12/19/18 TT transferred ownership from NCIP to NCI Standards. Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6580693","version":"1","preferredName":"Hepatocellular Carcinoma American Joint Committee on Cancer Edition 8 T Category","preferredDefinition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"6580693v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T3","valueDescription":"Hepatocellular Carcinoma pT3 TNM Finding v8","ValueMeaning":{"publicId":"6580697","version":"1","preferredName":"Hepatocellular Carcinoma pT3 TNM Finding v8","longName":"6580697","preferredDefinition":"Hepatocellular carcinoma with multiple tumors, at least one of which is larger than 5 cm. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT3 TNM Finding v8","conceptCode":"C134477","definition":"Hepatocellular carcinoma with multiple tumors, at least one of which is larger than 5 cm. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1A54-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1A6D-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T4","valueDescription":"Hepatocellular Carcinoma pT4 TNM Finding v8","ValueMeaning":{"publicId":"6580695","version":"1","preferredName":"Hepatocellular Carcinoma pT4 TNM Finding v8","longName":"6580695","preferredDefinition":"Hepatocellular carcinoma with single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT4 TNM Finding v8","conceptCode":"C134479","definition":"Hepatocellular carcinoma with single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1A2E-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1A47-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T2","valueDescription":"Hepatocellular Carcinoma pT2 TNM Finding v8","ValueMeaning":{"publicId":"6580699","version":"1","preferredName":"Hepatocellular Carcinoma pT2 TNM Finding v8","longName":"6580699","preferredDefinition":"Hepatocellular carcinoma with solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT2 TNM Finding v8","conceptCode":"C134476","definition":"Hepatocellular carcinoma with solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1A7A-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1A93-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T1b","valueDescription":"Hepatocellular Carcinoma pT1b TNM Finding v8","ValueMeaning":{"publicId":"6580701","version":"1","preferredName":"Hepatocellular Carcinoma pT1b TNM Finding v8","longName":"6580701","preferredDefinition":"Hepatocellular carcinoma with solitary tumor larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT1b TNM Finding v8","conceptCode":"C134475","definition":"Hepatocellular carcinoma with solitary tumor larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1AA0-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1AB9-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T1a","valueDescription":"Hepatocellular Carcinoma pT1a TNM Finding v8","ValueMeaning":{"publicId":"6580703","version":"1","preferredName":"Hepatocellular Carcinoma pT1a TNM Finding v8","longName":"6580703","preferredDefinition":"Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT1a TNM Finding v8","conceptCode":"C134474","definition":"Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1AC6-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1ADF-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T1","valueDescription":"Hepatocellular Carcinoma pT1 TNM Finding v8","ValueMeaning":{"publicId":"6580705","version":"1","preferredName":"Hepatocellular Carcinoma pT1 TNM Finding v8","longName":"6580705","preferredDefinition":"Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm, or larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT1 TNM Finding v8","conceptCode":"C134472","definition":"Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm, or larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1AEC-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1B05-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"T0","valueDescription":"Hepatocellular Carcinoma pT0 TNM Finding v8","ValueMeaning":{"publicId":"6580707","version":"1","preferredName":"Hepatocellular Carcinoma pT0 TNM Finding v8","longName":"6580707","preferredDefinition":"Hepatocellular carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pT0 TNM Finding v8","conceptCode":"C134471","definition":"Hepatocellular carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1B12-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1B2B-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"TX","valueDescription":"Hepatocellular Carcinoma pTX TNM Finding v8","ValueMeaning":{"publicId":"6580709","version":"1","preferredName":"Hepatocellular Carcinoma pTX TNM Finding v8","longName":"6580709","preferredDefinition":"Hepatocellular carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pTX TNM Finding v8","conceptCode":"C134470","definition":"Hepatocellular carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1B38-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FBDFE-1B51-61ED-E053-F662850A6D56","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6580692","version":"1","preferredName":"Hepatocellular Carcinoma TNM Finding v8 American Joint Committee on Cancer T Category Category","preferredDefinition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:A grouping of items based on some commonality or by user defined characteristics.","longName":"C134457:C39315:C25728:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma TNM Finding v8","conceptCode":"C134457","definition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FBDFE-1A01-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C5FBDFE-1A12-61ED-E053-F662850A6D56","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"TAYLORT","dateModified":"2019-09-04","changeDescription":"8-20-19 released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000438","version":"1","longName":"Liver","context":"NCI Standards"},{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779541","version":"1","longName":"LIHC Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"OCCPR","type":"USED_BY","context":"OCCPR"}],"ReferenceDocuments":[{"name":"Pathologic T category","type":"Preferred Question Text","description":"Pathologic T category","url":null,"context":"NCI Standards"},{"name":"CPTAC-BSLN-1","type":"Alternate Question Text","description":"Pathologic Primary Tumor Status (pT)","url":null,"context":"OCCPR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C5CAC40-B1A2-4866-E053-F662850A65EA","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeDescription":"8-30-19 TMT released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}